LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

LLY

1,047.45

-0.3%↓

JNJ

203.22

+0.34%↑

ABBV

229.4

-1.63%↓

UNH

313.56

+2.24%↑

AZN

88.84

-0.21%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Ouvert

3.51 -0.28

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.48

Max

3.64

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+24.31% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

148M

1.2B

Ouverture précédente

3.79

Clôture précédente

3.51

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 nov. 2025, 23:36 UTC

Actions en Tendance

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

19 nov. 2025, 22:13 UTC

Résultats
Acquisitions, Fusions, Rachats

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

19 nov. 2025, 21:55 UTC

Principaux Mouvements du Marché

Amgen Lung Cancer Drug Gets Full Approval From FDA

19 nov. 2025, 21:43 UTC

Acquisitions, Fusions, Rachats

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

19 nov. 2025, 23:55 UTC

Market Talk

Gold Rises on Possible Investment Demand -- Market Talk

19 nov. 2025, 23:54 UTC

Market Talk

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

19 nov. 2025, 23:47 UTC

Résultats

Lenovo Group 2Q EPS $2.52 >0992.HK

19 nov. 2025, 23:46 UTC

Résultats

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

19 nov. 2025, 23:45 UTC

Résultats

Lenovo Group 2Q Rev $20.5B >0992.HK

19 nov. 2025, 23:42 UTC

Market Talk

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

19 nov. 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

19 nov. 2025, 23:41 UTC

Résultats

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

19 nov. 2025, 23:41 UTC

Résultats

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

19 nov. 2025, 23:40 UTC

Résultats

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

19 nov. 2025, 22:55 UTC

Résultats

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

19 nov. 2025, 22:41 UTC

Résultats

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

19 nov. 2025, 22:30 UTC

Acquisitions, Fusions, Rachats

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

19 nov. 2025, 22:30 UTC

Résultats

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

19 nov. 2025, 22:30 UTC

Acquisitions, Fusions, Rachats

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

19 nov. 2025, 22:27 UTC

Acquisitions, Fusions, Rachats

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

19 nov. 2025, 22:08 UTC

Résultats

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

19 nov. 2025, 22:00 UTC

Résultats

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

19 nov. 2025, 21:58 UTC

Résultats
Acquisitions, Fusions, Rachats

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

19 nov. 2025, 21:52 UTC

Résultats

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

19 nov. 2025, 21:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

19 nov. 2025, 21:49 UTC

Market Talk
Résultats

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

19 nov. 2025, 21:38 UTC

Résultats

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

19 nov. 2025, 21:28 UTC

Acquisitions, Fusions, Rachats

Palo Alto Networks to Buy Chronosphere for $3.35B

19 nov. 2025, 21:27 UTC

Acquisitions, Fusions, Rachats

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

19 nov. 2025, 21:24 UTC

Résultats
Acquisitions, Fusions, Rachats

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

24.31% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  24.31%

Haut 5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat